SG Americas Securities LLC Sells 102,478 Shares of Abbott Laboratories $ABT

SG Americas Securities LLC lowered its position in Abbott Laboratories (NYSE:ABT) by 9.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 962,793 shares of the healthcare product maker’s stock after selling 102,478 shares during the period. SG Americas Securities LLC owned 0.06% of Abbott Laboratories worth $120,628,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Charles Schwab Trust Co increased its stake in shares of Abbott Laboratories by 109.8% in the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after buying an additional 15,394 shares in the last quarter. Asset Management One Co. Ltd. lifted its position in Abbott Laboratories by 2.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock worth $115,032,000 after buying an additional 19,966 shares in the last quarter. Nordea Investment Management AB grew its holdings in Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after acquiring an additional 18,974 shares during the last quarter. AE Wealth Management LLC increased its position in Abbott Laboratories by 20.8% in the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock valued at $8,774,000 after acquiring an additional 11,264 shares in the last quarter. Finally, Mawer Investment Management Ltd. raised its stake in shares of Abbott Laboratories by 5.9% in the third quarter. Mawer Investment Management Ltd. now owns 1,255,780 shares of the healthcare product maker’s stock worth $168,199,000 after acquiring an additional 70,122 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In related news, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the sale, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. This represents a 0.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the sale, the vice president directly owned 24,628 shares in the company, valued at $2,846,504.24. The trade was a 2.32% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on ABT. Argus decreased their price target on shares of Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Piper Sandler reduced their price objective on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a report on Friday, January 23rd. Barclays decreased their price objective on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. BTIG Research lowered their target price on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Finally, The Goldman Sachs Group cut their price target on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $136.16.

Abbott Laboratories Stock Down 0.6%

Shares of Abbott Laboratories stock opened at $104.87 on Tuesday. Abbott Laboratories has a 12 month low of $104.10 and a 12 month high of $139.06. The business has a fifty day simple moving average of $112.36 and a 200 day simple moving average of $122.77. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The stock has a market cap of $182.65 billion, a PE ratio of 28.19, a price-to-earnings-growth ratio of 1.68 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s payout ratio is currently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.